At the European League Against Rheumatism (EULAR) meeting in Rome on 10-13 June, additional data from the Phase IIb BESTFIT trial with TNX-102 SL in fibromyalgia was presented. The product profile of an efficacious treatment with limited systemic side effects was confirmed. In May, Tonix announced they have launched the Phase III AFFIRM study with data expected in H216.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
EULAR data update
At the European League Against Rheumatism (EULAR) meeting in Rome on 10-13 June, additional data from the Phase IIb BESTFIT trial with TNX-102 SL in fibromyalgia was presented. The product profile of an efficacious treatment with limited systemic side effects was confirmed. In May, Tonix announced they have launched the Phase III AFFIRM study with data expected in H216.